Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial

NCT03786198 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03786198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03786198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial
Lead sponsor
Swiss Cancer Institute
Phase
Not applicable
Overall status
Completed
Start date
March 28, 2019
Completion date
June 8, 2023
Enrollment
375 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

early breast cancer